intraocular lymphoma (Cancer)
Information
- Disease name
- intraocular lymphoma
- Disease ID
- DOID:775
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01815749 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | October 8, 2013 | September 27, 2024 |
| NCT02213913 | Active, not recruiting | Phase 1/Phase 2 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | July 29, 2014 | July 29, 2023 |
| NCT00004241 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | October 1999 | |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00049504 | Completed | Phase 2 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | January 2002 | February 2014 |
| NCT00054639 | Completed | Phase 2 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | January 2003 | January 2010 |
| NCT00072514 | Completed | Phase 2 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | August 2003 | November 2013 |
| NCT00077155 | Completed | Phase 1 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | December 2003 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00089271 | Completed | Phase 1 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | July 2004 | |
| NCT00098891 | Completed | Phase 1 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | October 2004 | |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00221325 | Completed | Phase 1 | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | April 2007 | March 2013 |
| NCT00293345 | Completed | Phase 1 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | June 2006 | |
| NCT00348985 | Completed | Phase 1 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | March 2006 | |
| NCT02542514 | Completed | Phase 2 | Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma | September 2015 | December 1, 2021 |
| NCT00003970 | Completed | Phase 1 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | January 1999 | |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01523223 | Completed | Phase 1 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | January 2012 | October 2016 |
| NCT01542918 | Completed | Phase 1 | Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma | December 17, 2012 | August 30, 2016 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01658319 | Completed | Phase 1 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | May 2011 | May 2015 |
| NCT01722305 | Completed | Phase 1 | Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | April 8, 2013 | July 15, 2019 |
| NCT01748721 | Completed | Phase 1 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2013 | May 2015 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01959477 | Completed | Early Phase 1 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | March 2014 | April 2015 |
| NCT02037256 | Completed | N/A | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | July 2011 | January 21, 2015 |
| NCT00003196 | Completed | N/A | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | September 1997 | April 2002 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00499811 | Completed | Phase 1 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | June 2007 | |
| NCT00536601 | Completed | N/A | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | June 29, 2006 | July 9, 2018 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00720135 | Completed | Phase 1 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | January 2008 | July 2014 |
| NCT00867529 | Completed | Phase 2 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | February 2009 | March 26, 2015 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01110135 | Completed | Phase 2 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | August 2010 | |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01158274 | Completed | Phase 1 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | June 2010 | |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01805037 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | March 5, 2013 | December 31, 2018 |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT01116154 | Terminated | Phase 1 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | May 2010 | August 2010 |
| NCT02109224 | Terminated | Phase 1 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | September 2014 | July 2015 |
| NCT00354185 | Terminated | Phase 1 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | May 2006 | |
| NCT02168907 | Terminated | Phase 1 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | December 2014 | February 2015 |
| NCT01678443 | Terminated | Phase 1 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | September 1, 1999 | September 27, 2018 |
| NCT00089076 | Terminated | Phase 1/Phase 2 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | June 2004 | October 2009 |
| NCT01769222 | Terminated | Phase 1 | Ipilimumab and Local Radiation for Selected Solid Tumors | February 2013 | June 2015 |
| NCT00933985 | Terminated | Phase 1 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | June 2009 | April 2013 |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 | |
| NCT02281279 | Withdrawn | Phase 1/Phase 2 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | October 2016 |
- Disase is a (Disease Ontology)
- DOID:6903
- Cross Reference ID (Disease Ontology)
- MESH:D064090
- Cross Reference ID (Disease Ontology)
- NCI:C9184
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0281658
- Exact Synonym (Disease Ontology)
- primary intraocular lymphoma
- MeSH unique ID (MeSH (Medical Subject Headings))
- D064090